GLP1R and diabetes mellitus: To mitigate these risks, the American and European Diabetes Associations have issued guidelines recommending the avoidance of therapeutic inertia and the use of innovative antidiabetic agents with cardioprotective and renal protective effects, such as GLP-1 Ras and SGLT-2is [2,5,6,7].